EDAP-TMS_RGB-300dpi-20160111.png
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
March 27, 2024 07:00 ET | EDAP TMS S.A.
Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
March 13, 2024 07:00 ET | EDAP TMS S.A.
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
March 06, 2024 07:00 ET | EDAP TMS S.A.
LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
March 04, 2024 07:00 ET | EDAP TMS S.A.
Focal One HIFU has potential to address large market impacting thousands of women each year LYON, France, March 4, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
February 29, 2024 07:00 ET | EDAP TMS S.A.
Record full-year 2023 preliminary unaudited revenue of EUR 60.4 million ($65.4 million USD), an increase of 9.6% over full-year 2022, driven by 31.7% HIFU growth Record Q4 2023 preliminary unaudited...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
February 01, 2024 08:00 ET | EDAP TMS S.A.
60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
January 08, 2024 08:00 ET | EDAP TMS S.A.
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
January 02, 2024 08:00 ET | EDAP TMS S.A.
   LYON, France, January 2, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
December 12, 2023 08:00 ET | EDAP TMS S.A.
Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France LYON, France, December 12, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
December 06, 2023 16:30 ET | EDAP TMS S.A.
LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S.,...